BJUI Mini Reviews: Metastatic Non-Clear Cell Renal Cell Carcinoma: Current Therapeutic Options
This is a review of all available data from subgroup analyses of the global sorafenib and sunitinib expanded access programmes, current phase- III trials, and smaller multi- and single-centre studies focusing on the activity of targeted agents in these specific and rare renal cell carcinoma subtypes.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |
